(Washington Times) The head of a drug manufacturer that lobbied on behalf of “Obamacare” now has come out swinging on one key aspect of the plan — the requirement for more tax rebates for dual Medicaid-Medicare recipients.
Eli Lilly & Co. CEO John Lechleiter said the “dual-eligible” aspect of Obamacare is all wrong for industry innovation and advancement, The Daily Caller reported. He made the statements during a shareholder meeting in Indianapolis, where the company is headquartered, earlier this week.
“Dual eligible” refers to the ability of Medicaid recipients to simultaneously receive Medicare benefits. Mr. Obama in his State of the Union speech spoke of the need for drug companies to expand their tax rebate programs for these consumers, The Daily Caller reported.